Key facts
- This page summarizes Everett Rand Sutherland's Form 3 filing for Upstream Bio, Inc. (UPB).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Oct 2024, 20:42.
Everett Rand Sutherland - 10 Oct 2024 Form 3 Insider Report for Upstream Bio, Inc. (UPB)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- UPB
- Reported as of
- 10 Oct 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 10 Oct 2024, 20:42:18 UTC
- Prior SEC filing
- 01 Jul 2024
- Next SEC filing
- 07 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Gray, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Everett Rand Sutherland filed Form 3 for Upstream Bio, Inc. (UPB) on 10 Oct 2024.
Change
- Previous filing in this sequence was filed on 01 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
UPB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 866,704
- Exercise price
- $5.69
- Footnotes
- F1
UPB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,053,799
- Exercise price
- $6.59
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
25% of the shares underlying this option shall vest on April 1, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F2
25% of the shares underlying this option shall vest on April 5, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney